Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

New competitors could make their way through trials and into the market over the next five years, but Novo Nordisk's lucrative share of the GLP-1 agonist market seems intact for now, to say the least.

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company the United Bio-Technology (Hengqin) Co., as it looks to ...

Novo Nordisk A/S (NYSE:NVO ... we now think the pendulum has swung too far the other way,” According to 26 different analyst ratings, Novo (NYSE:NVO) has the highest target price of $168. ...

Novo Nordisk, meanwhile, said it expects to file for regulatory approval for CagriSema in the first quarter of 2026. Still, the company has some way to go to recoup some of the earlier hype around ...

The market feels uncertain for many investors, but this Vanguard ETF could be a good choice. Here's what to know.

SpaceX reportedly proposed investing $1.5 billion in Vietnam tied to its Starlink rollout, with the company also exploring ...

Ozempic can lead to weight loss; however, intuitive eating advocates believe listening to your body’s hunger signals garner ...